236 related articles for article (PubMed ID: 32319845)
21. Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Chen Y; Ye J; Zhu Z; Zhao W; Zhou J; Wu C; Tang H; Fan M; Li L; Lin Q; Xia Y; Li Y; Li J; Jia H; Lu S; Zhang Z; Zhao K
J Clin Oncol; 2019 Jul; 37(20):1695-1703. PubMed ID: 30920880
[TBL] [Abstract][Full Text] [Related]
22. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
23. Postoperative radiation therapy with or without concurrent chemotherapy for node-positive thoracic esophageal squamous cell carcinoma.
Chen J; Pan J; Liu J; Li J; Zhu K; Zheng X; Chen M; Chen M; Liao Z
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):671-7. PubMed ID: 23773390
[TBL] [Abstract][Full Text] [Related]
24. Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment.
Jeene PM; Versteijne E; van Berge Henegouwen MI; Bergmann JJ; Geijsen ED; Muller K; van Laarhoven HW; Hulshof MC
Dis Esophagus; 2017 Feb; 30(2):1-5. PubMed ID: 27766725
[TBL] [Abstract][Full Text] [Related]
25. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
Nomura M; Oze I; Kodaira T; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Tachibana H; Uemura N; Tajika M; Niwa Y; Muto M; Muro K
Int J Clin Oncol; 2016 Oct; 21(5):890-898. PubMed ID: 26980212
[TBL] [Abstract][Full Text] [Related]
26. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone.
Chen Y; Lu Y; Wang Y; Yang H; Xia Y; Chen M; Song H; Li T; Li D; Wang J; Li S; Wang J
Dis Esophagus; 2014; 27(2):134-40. PubMed ID: 23088212
[TBL] [Abstract][Full Text] [Related]
27. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
28. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
[TBL] [Abstract][Full Text] [Related]
29. Radiation field size and dose determine oncologic outcome in esophageal cancer.
Gemici C; Yaprak G; Batirel HF; Ilhan M; Mayadagli A
World J Surg Oncol; 2016 Oct; 14(1):263. PubMed ID: 27737673
[TBL] [Abstract][Full Text] [Related]
30. Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer.
Jiang DM; Sim HW; Espin-Garcia O; Chan BA; Natori A; Lim CH; Moignard S; Chen EX; Liu G; Darling G; Swallow CJ; Brar S; Brierley J; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Knox JJ; Jang RW; Elimova E
Oncology; 2021; 99(1):49-56. PubMed ID: 33053548
[TBL] [Abstract][Full Text] [Related]
31. A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma.
Xia Y; Li YH; Chen Y; Liu Q; Zhang JH; Deng JY; Ai TS; Zhu HT; Badakhshi H; Zhao KL
Int J Clin Oncol; 2018 Jun; 23(3):458-465. PubMed ID: 29435872
[TBL] [Abstract][Full Text] [Related]
32. Impact of postoperative chemoradiotherapy and chemoradiotherapy alone for esophageal cancer in North-West Iran.
Mirinezhad SK; Somi MH; Shirmohamadi M; Seyednejad F; Jangjoo AG; Ghojazadeh M; Mohammadzadeh M; Naseri AR; Nasiri B
Asian Pac J Cancer Prev; 2013; 14(6):3921-4. PubMed ID: 23886207
[TBL] [Abstract][Full Text] [Related]
33. Acute treatment-related toxicity in elderly patients with good performance status compared to young patients in locally advanced esophageal carcinoma treated by definitive chemoradiation: A retrospective comparative study.
Mohata S; Kumar HS; Sharma N; Jhakhar SL; Beniwal S; Harsh KK
J Cancer Res Ther; 2020; 16(1):116-119. PubMed ID: 32362620
[TBL] [Abstract][Full Text] [Related]
34. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy.
Davuluri R; Jiang W; Fang P; Xu C; Komaki R; Gomez DR; Welsh J; Cox JD; Crane CH; Hsu CC; Lin SH
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):128-135. PubMed ID: 28816138
[TBL] [Abstract][Full Text] [Related]
35. Impact of radiation schedule and chemotherapy duration in definitive chemoradiotherapy regimen for esophageal cancer.
Di Fiore F; Lecleire S; Galais MP; Rigal O; Vié B; David I; Hamidou H; Paillot B; Jacob JH; Michel P
Gastroenterol Clin Biol; 2006; 30(6-7):845-51. PubMed ID: 16885868
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer.
Yavas G; Yavas C; Sen E; Oner I; Celik C; Ata O
Int J Gynecol Cancer; 2019 Jan; 29(1):42-47. PubMed ID: 30640682
[TBL] [Abstract][Full Text] [Related]
37. Definitive chemoradiotherapy for advanced cervical cancer: should it be different in the elderly?
Caires IQ; Souza KT; Negrão MV; de Oliveira JA; Barroso-Sousa R; de Lima RC; Hoff PM; Diz Mdel P
Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():86-9. PubMed ID: 26182837
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
[TBL] [Abstract][Full Text] [Related]
39. Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients.
Bosch DJ; Muijs CT; Mul VE; Beukema JC; Hospers GA; Burgerhof JG; Plukker JT
Ann Surg Oncol; 2014 Feb; 21(2):605-11. PubMed ID: 24100962
[TBL] [Abstract][Full Text] [Related]
40. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
